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1. Introduction 
Chronic liver diseases (CLD) are common and may lead to fibrosis, cirrhosis, and hepatic 
malignancy. Detection and staging of liver fibrosis is crucial for management of patients 
with CLD. At present, liver biopsy is the standard method for staging fibrosis, but biopsies 
are poorly tolerated because they are invasive and associated with some discomfort and 
complications. In addition, limitations of biopsy include intra- and inter-observer variation 
and sampling error1,2. In recent years, a great interest and many studies have been dedicated 
to the development of noninvasive tests to substitute liver biopsy for fibrosis assessment 
and follow-up. Unfortunately, all of them have limitations and pitfalls. To discuss their 
advantages and deficiencies will be helpful in scientific research and clinical practice. 
2. Invasive measurements 
2.1 Liver biopsy 
Liver biopsy has been considered as the gold standard to confirm the clinical diagnosis, to 
assess the severity of necro-inflammation and fibrosis, to identify cofactors and 
comorbidities, and to monitor the efficacy of treatments since the first liver biopsy was 
performed by Paul Ehrlich in 1883 3. The procedure is particularly useful for diagnosing the 
earlier stages of fibrosis and identifying patients at high risk of progressing fibrosis, but it 
has also a number of limitations. The patient acceptance is pretty low because biopsy is 
expensive, invasive and associated with some discomfort and complications. Pain appears 
in about one fourth of patients, other complications including bleeding, biliary peritonitis, 
pneumothorax and a mortality rate about 0.01% 4. Sampling error of at least 24% is reported 
usually because of specimen fragmentation or inadequate length. Colloredo et al concluded 
that an optimum specimen should be at least 20 mm in length with 11 complete portal 
tracts1. Even with adequate-sized biopsies, the interpretation might be unreliable, because 
the distribution of necro-inflammation and fibrosis is not homogeneous, and liver biopsy 
samples only 1:50 000th of the mass of the liver.  
Several semi-quantitative scoring systems have been proposed to describe and quantify the 
necro-inflammation, steatosis and fibrosis in the liver, particularly for chronic viral hepatitis. 
These include the Knodell histological activity index (HAI) first proposed in 1981, then 
modified to the Scheuer system, the METAVIR system and the Ishak modified HAI 5. 
However, all the scoring systems could only provide qualitative descriptors to stage fibrosis, 
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and the staging of certain histopathological changes differ in different systems (Table 1). 
This could cause considerable intra- and inter-observer variation and difficulty in 
comparison 2.  
 
Pathologic Features Knodell Scheuer  METAVIR  Ishak 
No fibrosis 0 0 0 0 
Enlargement of some portal tracts 1 1 1 1 
Enlargement of most portal tracts 1 1 1 2 
Periportal septa  1 2 1 2 
Occasional portal-portal septa 3 2 2 3 
Numerous septa (portal-portal and/or portal-central) 3 3 3 4 
Occasional nodules 4 4 4 5 
Definite cirrhosis 4 4 4 6 
Table 1. Scoring systems for staging fibrosis 
Using computerized digital image analysis, the amount of fibrosis in liver biopsy specimens 
can be evaluated by a quantitative score 6-9. Though it is thought to be less reliable in 
determining early stage fibrosis, recent advances such as a higher resolution digital camera 
can improve discrimination between the varying stages of liver fibrosis, including mild 
fibrosis 8. It may be a more precise method than semi-quantitative histological stages for 
monitoring fibrosis progression or regression during clinical therapeutic trials 9. 
Considering the irregular shape of specimens, fractal and spectral dimension analysis can 
also be used to improve accuracy 10.  
The detection of genes correlated with fibrosis from biopsy samples regains interest for liver 
biopsy. The changes in liver gene expression can indicate fibrosis progression precisely at an 
early stage 11. Genetic studies have identified possible genetic polymorphisms that influence 
the progression of liver fibrosis 12. The identification of panels of key genes correlating with 
differences in the progression of CLDs could lead to establishing excellent 
prognostic/diagnostic tools. 
2.2 Hepatic venous pressure gradient 
Hepatic venous pressure gradient (HVPG), as an expression of intrahepatic resistance, does 
not exceed 5 mmHg in absence of significant fibrotic evolution. The measurement of HVPG 
is a validated, safe and highly reproducible technique. It may be considered as a dynamic 
marker of disease progression in patients with HCV and an end point in antiviral therapy, 
irrespective of antiviral response 13. However, the technique is invasive, expensive, requires 
technical expertise, and has low patient acceptance. 
3. Serological tests 
The limitations of liver biopsy led to the searching of noninvasive tests for assessment of 
liver fibrosis. Afdhal and Nunes et al 14 suggest the following criteria for an ideal marker of 
liver fibrosis: it should be liver specific; should not be influenced by alterations in liver, 
renal, or reticuloendothelial function; should measure one or more of the processes related 
to fibrosis (stage of fibrosis, activity of matrix deposition, or activity of matrix removal); and 
should be easy to perform. 
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3.1 Direct serum markers 
The key step in the pathophysiology of liver fibrosis is the balance between ECM 
deposition and removal. Accumulation of ECM results from both increased synthesis and 
decreased degradation. The principal ECM constituents are synthesized by activated 
HSCs, while broken down by a family of enzymes known as matrix metalloproteinases 
(MMPs). Many studies have been dedicated to find serum ECM markers for fibrosis 
assessment. 
Hyaluronic acid (HA), a glycosaminoglycan distributed in the connective tissue, is a 
component of the liver extracellular matrix, which is synthesized and degraded in the liver 
sinusoidal cells. The high levels of HA observed in patients with chronic liver disease, have 
been related with a decreased function of the endothelial sinusoidal cells. Many studies 
showing a close relationship between liver fibrosis and HA levels.  
These similar markers of fibrosis incuding: 皆 collagens: N-terminal peptide of type ⊂ pro-
collagen (P⊂NP), type ⊃ collagen 7s domain(⊃-7S) 15, 絵 proteoglycans: hyaluronic acid 
(HA) 16, 芥 glycoproteins: laminin (LN) 17, human cartilage glycoprotein 39 (YKL-40) 18, 蟹 
collagenases and their inhibitors: MMPs, tissue inhibitor of metalloproteinases (TIMPs) 19, 開 
cytokines: transforming growth factor ǃ1 (TGF-ǃ1), platelet-derived growth factor (PDGF), 
tumor necrosis factor ǃ (TNF-ǃ).  
The clinical applications of such markers appear innovative, they are useful to assess the 
speed of liver fibrogenesis and estimate the response to anti-viral therapies or anti-fibrotic 
drugs. But most of them are insensitive in milder fibrosis, and it must be stressed that these 
markers reflect fibrogenesis and fibrolysis more than fibrosis itself. In other words, there 
may be a highly active fibrotic process in the liver, although fibrotic tissue has not yet been 
developed, or there may be heavy fibrosis in the liver but fibrotic activity is temporarily 
discontinued.  
3.2 Serum marker panels 
Since present direct markers could not satisfy the clinical need of measuring the fibrosis yet, 
an alternative approach turns out to be combining a number of serum markers to generate 
algorithms capable of evaluating fibrosis. A large number of panels have been suggested by 
groups worldwide 20-49 (Table 2).  
These panels are mainly based on two kinds of markers, direct and indirect. Direct markers 
are those directly linked to the modifications in ECM metabolism, such as HA and PヮNP. 
Indirect markers include a broad range of blood tests which have no direct link with liver 
fibrosis. They reflect liver dysfunction or other phenomena caused by fibrosis rather than 
fibrosis per se. Generally speaking, indexes including direct markers, such as the 
Fibrometer, may perform a higher accuracy, but indexes composed by only indirect markers 
are effective as well, and usually more useful because they are based on routine blood tests 
easy to be performed in a hospital general laboratory. 
The diagnostic value of the models was assessed by calculating the area under the receiver 
operating characteristic curves (AUROC). Most studies reported an AUROC >0.80 in 
differentiating significant fibrosis (fibrosis spread out the portal tract with septa) from 
no/mild fibrosis (no fibrosis or portal fibrosis without septa), improved performance with a 
higher AUROC value was showed in differentiating between no cirrhosis and cirrhosis. But 
it must be underlined that the AUROC values in table 2 came from each different designed 
study and are not suitable to make a comparison.  
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Index, Author, year, reference Patients no. CLDs markers in panel AUROC(T-V) a  
AAR, Williams, 1988 20 177 Mixed AST/ALT-ratio (AAR) n/a 
PGA index, Poynard , 1991 21 624 Alcohol  PT, GGT, apoA1 n/a 
PGAA index, Naveau , 199422 525 Alcohol  PT, GGT, apoA1, A2M n/a 
CDS index, Bonacini, 1997 23 75 HCV PLT, AAR, PT n/a 
AP index, Poynard 1997 24 620 HCV Age, PLT 0.763-0.690 
BAAT score, Ratziu 2000 25 93 NAFLD Age, BMI, ALT, TG 0.84 
Fortunato, 2001 26 103 HCV 
Fibronectin, prothrombin, ALT, PCHE, 
Mn-SOD, ǃ-NAG n/a 
Pohl, 2001 27 211 HCV AAR, PLT n/a 
FibroTest, Imbert-Bismut, 2001 28 339 HCV A2M, Hpt, GGT,  ApoA1, bilirubin 0.836-0.870 
Kaul 2002 29 264 HCV PLT, AST, sex, spider naevi n/a 
Forns index, Forns, 2002 30 476 HCV  Age, GGT, cholesterol, PLT 0.86-0.81 
APRI, Wai, 2003 31 270 HCV AST, PLT  0.80-0.88 
ELF-score, Rosenberg, 200432 1021 Mixed Age, HA, PヮNP, TIMP-1 0.804 
FIBROSpect II, Patel, 2004 33 696 HCV HA, TIMP-1, A2M 0.831-0.823 
FPI, Sud, 2004 34 302 HCV 
Age, AST, TC, HOMA-IR, past alcohol 
intake 
0.84-0.77 
MP3, Leroy, 2004 35 194 HCV PヮNP, MMP-1 0.82 
HALT-C, Lok, 2005 36 1141 HCV PLT, AAR, INR 0.78-0.81d 
Hepascore, Adams, 2005 37 221 HCV Bilirubin, GGT, HA, A2M, age, sex 0.85-0.82 
Fibrometer, Cales, 2005 38 383 Mixed PLT, PI, AST, A2M, HA, urea, age 0.883-0.892 
SHASTA index, Kelleher, 2005 39 95 HCV/HIV HA,AST and albumin 0.878 
Sakugawa, 2005 40 112 NAFLD ワ-7S, HA n/a 
Hui,2005 41 235 HBV BMI, PLT, albumin, TB, ALP 0.803-0.765 
SLFG, Zeng, 2005 42 372 HBV A2M, age, GGT, HA 0.84-0.77 
FIB-4, Sterling, 2006 43 832 HCV/HIV Age, AST, ALT, PLT 0.765b 
Virahep-C, Fontana, 2006 44 399 HCV age, AST, ALP,PLT 0.837-0.851 
Mohamadnejad, 2006 45 276 HBV HBV DNA levels, ALP, albumin, PLT, 0.91-0.85 
FibroIndex, Koda, 2007 46 402 HCV PLT, AST, Ǆ- globulin 0.828-0.835 
Alsatie, 2007 47 286 HCV 
diabetes mellitus, PLT, AST, INR, 
bilirubin 
0.79-0.75c 
Esmat, 2007 48 220 HCV HA, age 0.84b 
NAFLD fibrosis score, Angulo, 
2007 49 
733 NAFLD 
Age, BMI, PLT, albumin, AAR, 
hyperglycemia 
0.88-0.82 
a The area under the receiver operating characteristic curves (AUROC) for the diagnosis of significant 
fibrosis (stage 2-4 by the METAVIR or Scheuer classification, 3-6 by the Ishak score). T-V means the 
AUROC values of training group and validation group.  
b Differentiation advanced fibrosis (Ishak 4-6) from mild to moderate fibrosis (Ishak 0-3).  
c Differentiation advanced hepatic fibrosis (defined as F3-F4 by METAVIR) from milder (F0-F2).  
d Differentiation cirrhosis from no cirrhosis. 
Abbreviations used: CLD, Chronic liver disease; ROC, receiver operating characteristic; AUROC, area 
under the ROC curve; AAR, AST/ALT-ratio; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; PT, prothrombin time; GGT, Ǆ-glutamyltransferase; apoA1, apolipoprotein A1; A2M, 
ǂ2-macroglobulin; PLT, platelet count; TG, triglycerides; PCHE, pseudocholinesterase; Mn-SOD, 
manganese superoxide dismutase; ǃ-NAG, N-acetyl ǃ-glucosaminidase; Hpt, haptoglobin; HA, 
hyaluronic acid; P⊂NP, N-terminal peptide of type ⊂ pro-collagen; TIMP-1, tissue inhibitor of 
metalloproteinase 1; TC, total cholesterol; HOMA-IR, Homeostasis Model Assessment insulin 
resistance(fast glucose×plasma gluc/22.5); MMP-1, metalloproteinase 1; INR, international normalized 
ratio; PI, Prothrombin index; ⊃-7S, type ⊃ collagen 7s domain; BMI, body mass index; TB, total 
bilirubin; ALP, alkaline phosphatase.  
Table 2. Studies of serum markers panels for assessment of liver fibrosis 
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Chronic hepatitis B (CHB) is the most frequent infectious cause of CLD worldwide. More 
than 400 million people are chronically infected with HBV. The virus is responsible for more 
than 300,000 cases of liver cancer every year and for similar numbers of gastrointestinal 
haemorrhage and ascites 50. Predictive models designed specially for CHB patients have 
been proposed by the Shanghai Liver Fibrosis Group (SLFG) 42, Hui et al 41 and 
Mohamadnejad et al 45. But few of these models mentioned above has been widely validated 
and implemented in clinical practice. In our study of the S index 51, a simpler noninvasive 
model  based on routine laboratory markers,  we compare its diagnostic value with that of 
some typical models (Fig. 1), We noticed that the SLFG model and Hepascore performed 
better in identifying significant fibrosis than the Forns score and APRI, but the superiority 
was not so significant in identifying advanced fibrosis or cirrhosis. The result was similar to 
a validation study in CHC patients 52, indicating that such special tests might improve the 
sensitivity of a diagnostic model in predicting early fibrosis. But including tests unavailable 
in daily practice makes standardization, validation and routine bedside use difficult.  
 
Fig. 1. ROC curves in the prediction of significant fibrosis  
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There are still some limitations of these marker panels to be considered. First, the design of 
every study differed in population characteristic, patient selection, significant fibrosis 
prevalence, blood test inclusion, biochemical measurement and liver histological 
assessment, resulted in various panels with different markers and parameters. The 
agreement among these indexes is poor and validation study is needed to choose a proper 
panel and cutoff value for clinical use. Second, none of the studies controlled for degree of 
necro-inflammatory activity, most of the panels include markers likely to reflect or be 
affected by inflammation in the liver, which is much more mobile than fibrosis stage. Third, 
the formulae are easy to fail because many markers included will be influenced by 
extrahepatic diseases or conditions such as inflammation, haemolysis, cholestasis, 
hypercholesterolaemia and renal failure. Finally, few of the studies include treated patients. 
It is not clear whether these indexes are suitable for assessing treatment response. However, 
a few studies by Poynard et al suggested that Fibrotest could also be used as surrogate 
markers of the histological impact of treatments in patients infected by HCV and HBV 53, 54. 
These indexes, in their current form, are not able to give us the exact stage of fibrosis in most 
studies. Their main value is to reduce the need for liver biopsy by distinguishing significant 
fibrosis from no/mild fibrosis, and telling the presence of cirrhosis. It does not seem 
appropriate to completely replace liver biopsy with serum marker panels at the present time, 
but it can be anticipated that these indexes will become very useful in the clinical management 
of CLDs by offering an attractive alternative to liver biopsy, as they are noninvasive, 
convenient, inexpensive, and may allow dynamic assessment of fibrosis. Validation in larger 
cohorts of patients with different CLDs is needed before an index will be proposed for 
extensive clinical use. 
3.3 Proteomics and glycomics 
Over the last 5-6 years, it was reported that the use of proteomic patterns in serum to 
distinguish individual stages of fibrosis could achieve perfect diagnostic sensitivity and 
specificity. Using a proteome-based fingerprinting model generated by surface-enhanced laser 
desorption/ ionization time-of-flight (SELDI-TOF) ProteinChip arrays,  Poon et al 55 achieved 
an AUROC of 0.93 in identifying significant fibrosis. Another proteomic index combining eight 
peaks established by Morra et al 56 could diagnosis advanced fibrosis with an AUROC of 0.88, 
significantly greater than the FibroTest AUROC of 0.81. Besides, The SELDI-TOF ProteinChip 
technology is useful for the early detection and prediction of HCC in patients with chronic 
HCV infection 57. Similar technologies were also used to generate profiles of serum N-glycan 
profile for identifying liver fibrosis 58, 59. Further studies identifying the altered peaks in these 
models to understand their origins may help to find new biomarks for fibrosis, or even 
improve our understanding in the mechanism of liver fibrosis.  
4. Radiological tests 
Since significant structural changes are present only in advanced CLDs, the routine 
examinations by Ultrasound (US), computed tomography (CT) and magnetic resonance 
imaging (MRI) could bring specific findings, but with very limited sensitivity. Thus, 
persistent efforts were made to search for technological developments.  
4.1 Perfusion examinations 
MR and Doppler US techniques are studied to find sensitive perfusion changes in the 
progression of fibrosis 60. For example, the circulatory changes will result in a decrease of 
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hepatic vein transit time (HVTT), which can be measured by microbubble-enhanced US 61. 
Using HVTT measurements, Lim et al achieved 100% sensitivity and 80% specificity for 
diagnosis of cirrhosis, and 95% sensitivity and 86% specificity for differentiation of mild 
hepatitis from more severe liver disease 62. Progressive liver fibrosis gradually obliterates 
normal intrahepatic vessels and sinusoids and slows passage of blood through the 
parenchyma. In addition, as portal hypertension develops, portal venous flow to the liver 
decreases, hepatic arterial flow increases, and intrahepatic shunts form. These physiologic 
alterations can be detected with kinetic models of dynamic image data sets acquired rapidly 
after bolus intravenous injection of paramagnetic extracellular contrast agents. Several 
perfusion parameters can be estimated by MR perfusion imaging, a recent study applied a 
dual-input kinetic model for the noninvasive assessment of liver fibrosis. The dual-input 
approach models two sources of blood flow into the liver, via the he patic artery and portal 
vein, and assumes a single tissue compartment. Significant differences were found in several 
perfusion parameters between patients with and without advanced fibrosis 63. 
4.2 Liver stiffness measurement 
In chronic liver disease, progressive deposition of interconnecting collagen fibers 
throughout the liver produces a lattice-like framework that increases parenchymal rigidity. 
Because liver stiffness cannot be reliably assessed with external physical palpation, an 
imaging approach is required. There are two main imaging methods for measuring hepatic 
stiffness. One is US-based transient elastography; the other is MR elastography. 
The FibroScan, a new medical device based on one-dimensional transient elastography 64, 
which assesses fibrosis through liver stiffness measurement (LSM). A special probe 
generates an elastic shear wave propagating through the liver tissue, the harder the tissue, 
the faster the shear wave propagates. Transient elastography could accurately predict 
different stages of fibrosis or cirrhosis (AUROC: 0.79 for F ≥ 2, 0.91 for F ≥ 3, and 0.97 for F = 
4. by the METAVIR scoring system) 65.  
The major advantage of transient elastography compared with serum markers and marker 
panels is that it measures directly on the liver and there is no interference from extrahepatic 
diseases or conditions. Further more, the test is standardized and completely noninvasive. 
Though assessing earlier fibrosis is the common shortcoming of various noninvasive tests, 
Colletta et al reported that the agreement between transient elastography and liver biopsy was 
much better than FibroTest in normal transaminases HCV carriers with early stages of fibrosis66. 
Compared to liver biopsy, transient elastography is painless, rapid, has no risk of 
complications, and is therefore very well accepted. Transient elastography measures liver 
stiffness of a volume which is 100 times bigger than the biopsy specimen. The high 
reproducibility (intra- and inter-observer agreement intraclass correlation coefficient was 
0.98 67) and acceptance of transient elastography makes it an attractive alternative to biopsy 
for individual follow-up.  
There are also some physical limitations of transient elastography. The signal penetrates 
only 25–65 mm, makes obesity (particularly the fatness of the chest wall) the most important 
cause of failure68. But new technological developments may overcome the limitation. 
Additional limitations include a narrow intercostal space and ascites. The main reason that 
transient elastography can not totally replace liver biopsy is that it is only a means to stage 
disease. It is unable to diagnose liver disease by distinguishing subtle diagnostic differences. 
Nor can transient elastography identify cofactors and comorbidities or grade necro-
inflammation and steatosis. But it represents a totally different approach to assess fibrosis 
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and therefore could be combined with other noninvasive modalities to better assess liver 
fibrosis. The combined use of transient elastography and FibroTest to evaluate liver fibrosis 
could avoid a biopsy procedure in most patients with chronic hepatitis C 69.  
Magnetic resonance elastography (MRE) is a technique using a modified phase-contrast 
magnetic resonance imaging sequence to image propagating shear waves in tissue 70. The 
technique has been previously applied to quantitatively assess the viscoelastic properties of 
the breast, brain, and muscle in humans. Several recent studies showed that MRE is also a 
feasible method to assess the stage of liver fibrosis. Liver stiffness as measured with MR 
elastography increases as the stage of fibrosis advances. The differences in stiffness between 
patients with early stages of fibrosis (F0 vs F1 vs F2) are small and there is overlap between 
groups, but the differences between groups with higher stages (F2 vs F3 vs F4) are large, 
with little overlap between groups71. MRE has several potential advantages compared with 
ultrasound transient elastography. It can be performed in obesity patients. It can assess 
larger volumes and provide full three-dimensional information about the viscoelastic 
parameters of tissues. With MR techniques, a comprehensive examination of the liver can be 
performed, including MRE, contrast-enhanced MRI to detect hepatocellular carcinomas and 
perfusion MRI to assess liver function.  
4.3 Real-time elastography 
Real-time elastography is another ultrasound technique developed by Hitachi Medical 
Systems that can reveal the physical property of tissue using conventional ultrasound probes 
during a routine sonography examination. In the first study assessing real-time elastography 
for the detection of liver fibrosis 72, the AUROC was 0.75 for the diagnosis of significant 
fibrosis. Much higher diagnostic accuracy (AUROC = 0.93) was obtained by a mathematic 
combination of the elasticity score and two routine laboratory values (platelet count and GGT), 
which provided a more superior way to combine serological and radiological tests together. 
4.4 Double contrast material-enhanced magnetic resonance imaging 
The conspicuity of gadolinium-enhanced lesions is increased in the setting of decreased 
signal intensity from the uninvolved liver parenchyma following superparamagnetic iron 
oxide (SPIO) injection. This MRI technique has been used to improve detection of focal 
hepatic lesion and hepatocellular carcinoma 73, 74. Recently, Aguirre et al 75 examined 101 
CLD patients who underwent double-enhanced MR imaging to detect hyperintense 
reticulations, which are postulated to represent septal fibrosis. They achieved an accuracy of 
greater than 90% for the diagnosis of advanced hepatic fibrosis compared with 
histopathological analysis. Clinical trials are currently under way to prospectively assess 
fibrosis staging with this technique. 
4.5 Diffusion weighted magnetic resonance imaging 
Diffusion weighted magnetic resonance imaging (DWMRI) has been widely used in brain 
imaging for the evaluation of acute ischemic stroke. With the advent of the echo-planar MRI 
technique, it became possible to be applied in the abdomen for characterization of focal 
hepatic lesions 76. Recently, using DWMRI to measure the apparent diffusion coefficient 
(ADC) of water, a parameter that is dependent on the tissue structure, is introduced in the 
assessment of liver fibrosis 77. The ADC value is lower in livers with heavier fibrosis because 
of the restriction of water diffusion in fibrotic tissue. Lewin et al assessed the performance of 
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DWMRI in 54 patients with chronic HCV infection with reference to several other 
noninvasive methods 78. In discriminating significant fibrosis patients, the AUC values were 
0.79 for DWMRI, 0.87 for transient elastography, 0.68 for FibroTest, 0.81 for APRI, 0.72 for 
the Forns index, and 0.77 for hyaluronate. DWMRI performed better in discriminating 
patients staged F3-F4, the AUC value increased to 0.92, the same as transient elastography. 
But besides fibrosis, it seems that ADC values might also reflect the intensity of 
inflammation, necrosis and steatosis. Because technical factors lead to differences in 
estimated ADC, reported ADCs are variable, with considerable overlap between normal and 
abnormal ranges. Thus, there is a need to develop site- and technique-specific normal ranges 
and to standardize methods across imaging centers.   
Several other MR techniques have also been introduced in the area of fibrosis assessment, 
such as ultrashort echo time (UTE) MRI 79 and magnetic resonance spectroscopy (MRS) 80. 
New MR imaging contrast agents that specifically target collagen or other extracellular 
matrix macromolecules may be developed. A collagen-specific MR imaging contrast agent 
could act as a fibrosis-imaging agent, and these agents may have higher efficacy for fibrosis 
assessment than the current methods 81. All such data may provide valuable information for 
guiding antifibrotic therapy development and monitoring patients in clinical trials. 
5. Conclusion 
The increasing of potentially effective managements for CLDs such as antiviral and antifibrotic 
therapies has led to an urgent need for a rapid, safe and repeatable tool to assess fibrosis of 
CLDs and to follow-up progression or regression of fibrosis during treatment. Liver biopsy 
has been the gold standard for the assessment of hepatic fibrosis, but the invasive procedure 
has considerable limitations and fails to satisfy the current needs. Many noninvasive methods 
have been proposed with the aim of substituting liver biopsy. The numerous advances in 
serological, radiological techniques and their combinations have allowed to satisfactorily 
identify patients without a liver biopsy. But each of them has some deficiencies and the liver 
biopsy will still have an important role to play. Applying new techniques for the detection of 
fibrosis may potentially circumvent the pitfalls and deficiencies of the existing surrogates 
mentioned above. These include serum proteomics, glycomics and new imaging techniques 
such as molecular imaging technique for the imaging of cellular biochemical processes 82, 
diffraction-enhanced imaging technique for the imaging of soft tissues 83, photonic imaging 
technique for three-dimensional whole-body images 84. However, further studies are needed to 
develop or validate noninvasive tests that can accurately reflect the full spectrum of hepatic 
fibrosis in CLDs. But an incorrigible defect in our studies will be the questionable gold 
standard we have to use. More errors are due to the histological staging 85. Mathematical 
modeling suggested that assuming either 80% or 90% diagnostic accuracy of liver biopsy, 
noninvasive tests cannot achieve an AUROC better than 0.9 and are likely to perform between 
0.75 and 0.9 86, exactly where they are today. We may find a better surrogate for liver biopsy, 
but how can we prove it will be a question. Laparoscopic biopsy can decrease sampling error 
and increases the reliability of histopathologic assessment 87. Using automated image analysis 
to assess texture features and shape representation of the fibrosis structural expansion can turn 
the current semiquantitative methods of liver fibrosis assessment into real quantitative ones 
with significant reduction in variability and subjectivity 88. Validating noninvasive tests against 
not only histological stage scores but also digital image analysis and clinical outcomes may 
also be a better choice. 
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